
REPL Stock Forecast & Price Target
REPL Analyst Ratings
Bulls say
Replimune Group Inc has significantly raised its probability of approval for the RP1 + Opdivo combination in anti-PD1 failed melanoma patients to 85%, up from 50%, supported by promising trial results. The safety profile of RP1 + Opdivo is favorable, with only 12.8% of patients experiencing grade 3 or higher treatment-related adverse events, indicating a potential for successful market entry. This positive outlook is further bolstered by the overall encouraging data from the IGNYTE trial, which may enhance the company's positioning within the biotechnology sector.
Bears say
Replimune Group Inc faces significant challenges that contribute to a negative outlook on its stock, primarily stemming from its inability to produce compelling efficacy and safety data for its lead product candidate, RP1, in future clinical trials. The company has encountered setbacks related to regulatory approvals, including a Complete Response Letter (CRL) from the FDA highlighting deficiencies in the clinical trial design and data quality of the IGNYTE trial. Additionally, there is a looming risk of medium- to long-term dilution due to potential financial needs, further complicating the company's path toward delivering on its pipeline of oncolytic virus candidates.
This aggregate rating is based on analysts' research of Replimune Group Inc and is not a guaranteed prediction by Public.com or investment advice.
REPL Analyst Forecast & Price Prediction
Start investing in REPL
Order type
Buy in
Order amount
Est. shares
0 shares